TimesSquare Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

TimesSquare Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-360,200	Closed	-$6.76M	–	264
2018 Q1	$6.76M	Sell	360,200 -9,300	-3%	-$163K	0.05%	228
2017 Q4	$6.71M	Sell	369,500 -15,700	-4%	-$332K	0.04%	229
2017 Q3	$8.57M	Buy	+385,200	New	+$8.45M	0.06%	227

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TimesSquare Capital Management's SNNA Position: Q2 2018 in Review

TimesSquare Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2018, closing a stake of 360,200 shares — an estimated $6.76M sold.

TimesSquare Capital Management first reported a position in SNNA in Q3 2017 and held it in 3 quarters. The position peaked at $8.57M in Q3 2017. 53 funds tracked by Wall St. Rank hold SNNA as of Q2 2018.

TimesSquare Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
TimesSquare Capital Management sold 360,200 Sienna Biopharmaceuticals, Inc. shares in Q2 2018, an estimated $6.76M.
TimesSquare Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
TimesSquare Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $8.57M in Q3 2017.
53 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2018.

Based on TimesSquare Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.